AGC Biologics vs FUJIFILM Diosynth Biotechnologies: CDMO Comparison

How does AGC Biologics compare to FUJIFILM Diosynth Biotechnologies for AAV manufacturing?

Side-by-side comparison of AGC Biologics and FUJIFILM Diosynth Biotechnologies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score
78/100
Quality (FDA + GMP)
100/100
FDA inspections
4
— NAI / VAI / OAI
1 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
27
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
2
Capacity
Available
Modalities
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score
85/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
29
MHRA GMP certificates (compliant)
6
Clinical programs (matched)
0
Capacity
Expanding
Modalities
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Key differences

  • AGC Biologics has more FDA inspections on record (4 vs 0) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • FUJIFILM Diosynth Biotechnologies maintains 6 MHRA / UK GMP certificates; AGC Biologics does not.

On a 13-modality CDMO landscape, both AGC Biologics and FUJIFILM Diosynth Biotechnologies qualify as AAV manufacturers; FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score for AAV programs in this comparison.

What to evaluate for AAV programs

Both AGC Biologics and FUJIFILM Diosynth Biotechnologies qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

See all AAV CDMOs ranked by Signal Score →

Frequently asked: AGC Biologics vs FUJIFILM Diosynth Biotechnologies

How does AGC Biologics compare to FUJIFILM Diosynth Biotechnologies for AAV manufacturing?

On CDMO Signal's composite Signal Score, AGC Biologics is 78/100 and FUJIFILM Diosynth Biotechnologies is 85/100; AGC Biologics has 4 FDA inspections on record vs 0 for FUJIFILM Diosynth Biotechnologies; European coverage is 27 active EMA+MHRA certificates for AGC Biologics vs 35 for FUJIFILM Diosynth Biotechnologies. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, AGC Biologics or FUJIFILM Diosynth Biotechnologies?

Both AGC Biologics and FUJIFILM Diosynth Biotechnologies maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 4 FDA inspections on record; FUJIFILM Diosynth Biotechnologies has 0.

How do AGC Biologics and FUJIFILM Diosynth Biotechnologies compare on European GMP coverage?

AGC Biologics holds 27 active EMA GMP certificates and 0 MHRA / UK certificates. FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — AGC Biologics or FUJIFILM Diosynth Biotechnologies?

AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; FUJIFILM Diosynth Biotechnologies is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for AAV manufacturing — AGC Biologics or FUJIFILM Diosynth Biotechnologies?

Both AGC Biologics and FUJIFILM Diosynth Biotechnologies are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.

Evaluating AGC Biologics and FUJIFILM Diosynth Biotechnologies for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.